V International Conference

Wija Oortwijn

Wija Oortwijn studied health sciences and holds a PhD in Medicine. Dr. Oortwijn has more than 20 years of relevant professional experience in policy analysis with regard to health care, life sciences and public health. Examples include the ex ante evaluation of the Draft EC Regulation on Medicinal Products for Paediatric Use. She led a project on the impact of HTA on prescribing patterns of diabetes and rheumatic arthritis drugs in Europe, the US, Canada and Australia and a project that assessed the impact of HTA in the process of pharmaceutical pricing and reimbursement in a selection of 10 middle-income countries. The outcomes of this research have been published in Health Policy. In addition, she developed an instrument to map the level of HTA at country level. This was applied to selected middle-income countries (Argentina, Brazil, India, Indonesia, Malaysia, Mexico and Russia) as well as to countries well-known for their comprehensive HTA programs (Australia, Canada and United Kingdom). The instrument and the results of the application were published in the International Journal of Technology Assessment in Health Care. Finally, she conducted a study on methods and processes that can support timely decisions on reimbursement of health technologies, especially in Brazil, Serbia, Slovakia and Taiwan. She has also coordinated and participated in different European collaboration networks focusing on HTA (Eurassess, HTA Europe, ECHAHI/ECHTA). She is also a founding Member of International Society for HTA (HTAi) and was involved in the organisation of several annual HTAi conferences. Furthermore, she is a member of the Editorial Board of the International Journal of Technology Assessment in Health Care.

Krzysztof Łanda

The Founder of Watch Health Care Foundation ( The CEO of MedInvest Scanner Ltd. General partner in HTA Audit, a company dealing with quality of HTA (Health Technology Assessment) reports directed to authorities and public institutions in Poland; expert of BCC on health care system. From 2010 till 2011 he was President of Central & Eastern European Society of Technology Assessment in Health Care. In 2006-2007 Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland. Dr Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr Landa organized many national and international HTA workshops and conferences. In years 2006 – 2008 Dr Landa provided consultancy for the Serbian Ministry of Health. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.

Vanesa Benkovic

Senior consultant HTA, HE and Research, Croatian Society for Pharmacoeconomics and Health Economics, Zagreb, Croatia. Vanesa Benkovic, graduated her masters study as manager in health and health services at Medical Faculty, University of Zagreb. She is currently finishing her PhD thesis on health inequalities at Faculty of Philosophy, Sociology Dpt. University of Zagreb. Vanesa graduated several educations in field of pharmacoeconomics, health economics and advanced modeling in HTA in France and Austria. She received Open Society scholarship at Global Health Economics project by European University of St. Petersburg, Russia. She teaches pharmacoeconomics and health economics at Faculty of Medicine, Faculty of Pharmacy University of Zagreb, and health statistics at European University of St. Petersburg GHE courses. Her field of work includes extensive list of health economic analysis for drugs, devices, technologies and cost of illness studies in Croatia, Slovenia and Bosnia and Herzegovina, as well as research methodology for various EU JA projects such as Urban health centers Europe and Cross border patient registries initiative (PARENT). She also designs and performs market and scientific research in health. Her latest engagements include health business intelligence for a World Bank project for Croatian Ministry of Health and strategic consultancy both for pharmaindustry and budget holders. She publishes papers in area of research methodology, public health, pharmacoeconomics and health economics. Currently Vanesa is setting up business including IT applications for polypharmacy.

Norbert Wilk

Norbert Wilk, Arcana Institute’s Consultancy Department Director. He was a deputy director for HTA and international cooperation of the Agency for Health Technology Assessment and Tariff System in Poland for 3 years. He is responsible for introducing a two-step system (assessment – appraisal) of preparing recommendations on financing health technologies in Poland which is evidence-based in compliance with EBM/HTA principles.
He was head of the Ministry of Health’s Accreditation Office, where his work lead to issuing the first practice quality standards by way of regulation – for medical diagnostic laboratories. He also worked on updating reimbursement lists in the Reimbursement and Prices Unit of the Ministry of Health’s Drug Policy and Pharmacy Department. He was a co-author of the first Polish HTA reports while working in the Standardisation Bureau of the Centre for Quality Monitoring in Health Care.

Angela Yu

Angela Yu graduated from Master’s Health Policy, Planning and Financing, offered jointly by the London School of Economics and the London School of Hygiene and Tropical Medicine in 2015. Prior to her Master’s, Angela worked as Management Consultant in China for 5 years with the group IMS Health. In her work as a Consultant, she was charged with providing multi-national biopharmaceutical companies, NGO’s and industry associations with strategies which helped to maximize opportunities in Pricing and Market Access. During her time in China, she also participated in many independently commissioned policy-analysis and policy-shaping projects, which aimed to ensure the future of China’s pricing and market access policies deliver sustainable growth for the nation, while meeting the needs of the Chinese population.

Mark Parker

Mark Parker is Senior Economic modeller for the University of Liverpool Health Economic Unit, Liverpool Cancer Trials Unit and Technical director of Evaluate Econ Ltd, UK. Early background was in software and electronic engineering (University of Manchester) and real time Digital Signal Processing, along with Radio Frequency design. Completed the MSc in Health Economics at the University of York, UK (2009).Currently PhD submission pending in Health Economic Modelling at the University of Liverpool. These roles have mostly involved developing models and evidence based messages for a wide range of disease areas for global value dossiers and HTA submissions to NICE, SMC and CVZ, along with internal decision-making. Working with GSK (vaccines), Sanofi Aventis (Diabetes), Wirral Primary Care Trust (Real world data validation), CHAMPS (weight management interventions) and Shire (biological in a chronic condition).Experience in a vast range of disease areas and population modelling, with a strong educational background in economics, software development, distributed systems and computation, Artificial Intelligence (1st, BSc Economics and Computer Science, UoL). Applying these skills to develop evidence based value arguments for Health Technology Assessment. This training, education and experience provide the means to apply the world’s most advanced techniques to solve complex problems in a methodical, transparent and comprehensible way, with a core focus on knowledge transfer. Mark enjoys a wide range of water, snow and motor sports.

Tanja Novakovic

Tanja Novakovic MSc Pharm is the president of the Pharmacoeconomics Section within the Pharmaceutical Association of Serbia (2006-to date). She is a founder of the ISPOR Serbian chapter and between 2007 and 2009 its vice president. Since 2001 she has been working in Galenika a.d., a pharmaceutical company, as a product manager for drugs for the central nervous system. Tanja Novakovic is a graduate of the University of Belgrade, Faculty of Pharmacy finishing her postgraduate studies at the Faculty of Pharmacy at Ghent University in Belgium. She is the author of the “Handbook for pharmacoeconomic evaluations”, the first such publication in the field of pharmacoeconomics in the Serbian language. Through the Pharmacoeconomics Section she is constantly increasing awareness of health economics, pharmacoeconomics and the importance of Health Technology Assessment. She is active in shaping healthcare policy, writing the first Guidelines for pharmacoeconomic evaluations for Serbia. She was also co-author in one of the three HTA reports first completed in Serbia, and was engaged to lead a group of experts to define all existing elements of basic benefit package in Serbia within the World Bank/Ministry of Health of Serbia projects. Tanja has organized and presented in many national meetings and international conferences which have resulted in international cooperation in education and the developing of pharmacoeconomics and HTA in Serbia.

Dávid Dankó

Dávid Dankó is managing director of Ideas & Solutions, a strategic advisory firm which works together with leading pharmaceutical and medical device manufacturers on making new medicines accessible for patients, as well as local portfolio strategies and patient adherence management. Dávid received his MSc degree in Economics at Corvinus in 2003, and a PhD degree in 2012 with his thesis on long-term resource management in the pharmaceutical industry. He has been the co-editor of a comprehensive textbook on reimbursement policy. Between 2003 and 2008, he worked as a consultant specialized in health care and life sciences, working with local and multinational companies as well as the Hungarian government. His consulting and expert assignments were mainly focused on health care reform, strategy formulation and implementation, and business planning. Between 2008 and 2010, he worked on the payer side, as deputy head for the strategy, analysis and integration of the Department of Reimbursement at the Hungarian National Health Insurance Fund Administration. There he was primarily responsible for pharmaceutical and medical device reimbursement strategy, concept development, international co-operations, and the co-ordination of IT development as well as research and analysis activities. Dávid Dankó is a lecturer at Vienna School of Clinical Research, Université Lyon 1 (EMAUD), Semmelweis University of Budapest, Eötvös Lorand University, and he a regular speaker at international workshops and conferences on pharmaceutical and medical device reimbursement.

Bojan Trkulja

Bojan Trkulja, director of the Association of Manufacturers of innovative medicines INOVIA in Belgrade, Serbia from 1st December 2010. He was born in 1971 in Belgrade, where he completed his elementary, high school and medical university. After a successful internship and passing the state exam, he worked in the office of F. Hoffmann - La Roche in Belgrade, from December 1999. Over the last 11 years he held a variety of positions, from associate through the Medical Product Manager, Compliance Officer and Market Access Manager. Bojan is happily married.

Brian Godman

Brian works with health authorities and health insurance companies across countries, including over 30 European countries and regions, to progress policies to enhance the quality and efficiency of care for both new and established medicines. This includes developing new models to optimise the managed entry of new medicines including those for oncology and orphan diseases. This builds on a background in consultancy and the pharmaceutical industry. These activities have resulted in over 100 publications in recent years in peer reviewed journals, many of which are listed in Pub Med. Brian will use his combined experiences to debate key issues regarding new cancer medicines and potential ways forward.

Günter Harms

After graduating as a Pharmacist and PhD from the University of Kiel, Germany, Dr Harms moved into a management role within the Institute for Public Health Systems Research; a consulting firm and WHO collaborating centre. His responsibilities included health economics, pharmacoepidemiology and healthcare systems research. In 1996 he joined the pharmaceutical industry working in drug development and regulatory affairs at Ferring GmbH in Germany. In 1999, Dr. Harms moved to a role with Novartis Pharma AG, initially in drug development. He subsequently took on strategic management positions in Novartis global headquarters in Basel, Switzerland and then within the US country organization. Returning from the US, as Director for Novartis Global Public Affairs, Dr. Harms was responsible for a broad portfolio of projects including market access, HTA, healthcare reform and cost containment issues. In 2009 - 2011 as Market Pricing Director for Novartis Pharma Dr. Harms was successively responsible for the implementation of Novartis pricing and reimbursement strategies in CEE, Turkey, Russia and CIS. In 2011 Dr. Harms joined Shire Human Genetic Therapies and currently is Market Access & Public Affairs Director, responsible for Central and Eastern Europe for Shire.

Jovan Mihajlovic

Jovan Mihajlovic, a health economist, is a PhD fellow at the University of Groningen, the Netherlands and owner of a consulting company Mihajlović Health Analytics (MiHA). He is a graduated pharmacist completing the PhD thesis “Economic Evaluation ofTargetedCancer Therapies in Serbia“. Jovan has an extensive experience within the pharmaceutical industry where he spent 7 years in the field of sales and marketing. Through MiHA he designed cost-effectiveness and budget impact models, conducted epidemiological/pharmaco-epidemiological studies, systematic reviews and network meta-analyses for academia and the industry in Serbia and the Netherlands. He published several studies in renowned medical journals and was speakerat numerous health economic and oncological professionals’ meetings.

Jakub Adamski

Jakub Adamski, attorney-at-law. He specialises in advising on market access and financing healthcare technologies financed from public funds, in particular on reimbursement of drugs, foodstuffs for particular nutritional uses and medical devices, as well as other healthcare system-related issues. He worked at the Drug Policy and Pharmacy Department for 6 years. As a chief expert he was responsible for inter alia reimbursement under the therapeutic and drug programmes, policy on orphan drugs and international cooperation on reimbursement of drugs. He is a former member of the Orphan Diseases Team (advisory body to the Minister of Health) and the European Union’s Committee of Experts on Rare Diseases. He represented the Minister of Health in EU Council and European Commission working groups and Member States’ networks on drug reimbursement. He is a co-author of several publications on pharmaceutical pricing and healthcare policy.
Session SFE SFUS - 7th Serbian Congress of Pharmacy
Friday 12th October 2018, Crowne Plaza Hotel, Belgrade, Serbia
Is Belgrade the New Berlin?
APRIL 6, 2017
No city makes you feel more like a New Yorker than Belgrade. In Belgrade, people don’t walk, they amble; lunch spans the course of 3 or 4 hours; and drinks are sipped, never knocked back. Despite the slow pace of life, there’s still an unmistakable energy that bursts through the city.
Preliminary Program

The preliminary program for the conference "THE VALUE OF INNOVATION IN DECISION MAKING" is now available. Use the link above or access from the menu in the top right.
VI International SFE SFUS Conference
2nd June 2017, Belgrade, hotel Metropol, Serbia.

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
Fifth International Conference - Speakers
9th and 10th of October 2015 Belgrade, hotel Metropol
Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden

Wija Oortwijn PhD, Partner at ECORYS NL, The Netherlands

Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland

Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK

Angela Yu MSc, London School of Economics, UK

Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank

Dávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary

Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany

Vanesa Benkovic MSc, Senior HTA and health research consultant, Croatia

Bojan Trkulja MD, Managing Director at INOVIA, Serbia

Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia, Representative of Chamber of Commerce and Industry of Serbia

Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institute, Poland

Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK

Norbert Wilk, Arcana Institute, Poland

Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia

Belgrade, 28th April 2015, hotel Crowne Plaza
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia
The objectives of the conference are:

• present the characteristics of biopharmaceutical medicines and biosimilars,

• understanding the nature of biopharmaceutical and biosimilar regulations,

• share clinical experience with biological medications and more generally

• exchanging experiences and knowledge with experts from the region and international stage.
Managed Introduction of new medicines
11 – 13 May 2015 - Warsaw, Poland
PIPERSKA workshop co-organised with the Agency for HTA & Tariff System in Poland and WHO Europe
This course is primarily intended for healthcare
professionals involved with enhancing the rational use
of medicines especially new medicines
Fifth Adriatic and Fourth Croatian Congress of Pharmacoeconomics and Outcomes Research
Šibenik, Croatia, from 23rd to 26th April 2015.
Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical Pharmacology and Therapeutics, Croatian Medical Association
This year focus will be on the following subjects: 'The role and impact of pharmaceutical industry on the general economy in countries in the region' and 'The need to adapt the model for health technology assessment in countries with high risk of sustainability of healthcare financing in order to ensure transparency and competitiveness'.
5th of February 2015 Crowne Plaza Hotel, Belgrade, SERBIA
SFUS Pharmacoeconomics Section
The purpose of the Conference is to:
• Introduce and present the importance and value of patient registries,
• Introduce health outcomes and treatment outcomes reported by patients,
• Exchange experiences across the countries that used data of patients registers in the
pharmacoeconomic analysis
• Introduce the examples of special agreements (Risk sharing, Pay per Performance)
HTA for Healthcare Quality Assurance
December 15th-16th, 2014, Kraków, Poland
CEESTAHC 9th International Symposium Evidence-Based Health Care 2014